title: Nanomedicines in the treatment of chronic hepatitis C--focus on pegylated interferon alpha-2a.
abstract: Nanotechnology is the application of nanotechnology within medicine. An illustration of this is the use of pegylation as a means of modifying naturally occurring proteins which may have clinical applications, in order to improve the pharmacodynamics of the protein resulting in an effective medication. An example of this is pegylated interferon. The purpose of this review is to examine the chemistry, clinical pharmacology, pharmacokinetics, pharmacodynamics, and clinical studies with 40 kDa pegylated interferon to illustrate the general principles of pegylated biological proteins. The use in clinical practice is reviewed along with the evidence for both efficiacy, safety, and advantages over standard interferon.
authors.affiliation: University College London Hospital NHS Trust, London.
authors.forename: Thea
authors.initials: T
authors.lastname: Thomas
authors.forename: Graham
authors.initials: G
authors.lastname: Foster
mesh_terms: D000998:Antiviral Agents / Q000008:administration & dosage / Q000737:chemistry; D002986:Clinical Trials as Topic / Q000639:trends*; D003692:Delayed-Action Preparations / Q000008:administration & dosage* / Q000737:chemistry; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage* / Q000737:chemistry; D050997:Nanomedicine / Q000379:methods / Q000639:trends*; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000737:chemistry*; D011994:Recombinant Proteins
chemical_list: D000998:Antiviral Agents; D003692:Delayed-Action Preparations; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C100416:peginterferon alfa-2a